AN2 THERAPEUTICS INC (ANTX) Stock Fundamental Analysis

NASDAQ:ANTX • US0373261058

1.09 USD
+0.06 (+5.83%)
At close: Feb 19, 2026
1.0954 USD
+0.01 (+0.5%)
After Hours: 2/19/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

ANTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ANTX as it has an excellent financial health rating, but there are worries on the profitability. ANTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ANTX has reported negative net income.
  • ANTX had a negative operating cash flow in the past year.
  • In the past 5 years ANTX always reported negative net income.
  • ANTX had a negative operating cash flow in each of the past 5 years.
ANTX Yearly Net Income VS EBIT VS OCF VS FCFANTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -50.55%, ANTX is doing worse than 63.35% of the companies in the same industry.
  • The Return On Equity of ANTX (-56.29%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -50.55%
ROE -56.29%
ROIC N/A
ROA(3y)-48.03%
ROA(5y)-106.84%
ROE(3y)-53.15%
ROE(5y)-145.1%
ROIC(3y)N/A
ROIC(5y)N/A
ANTX Yearly ROA, ROE, ROICANTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • ANTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANTX Yearly Profit, Operating, Gross MarginsANTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • ANTX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ANTX has more shares outstanding
  • ANTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANTX Yearly Shares OutstandingANTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANTX Yearly Total Debt VS Total AssetsANTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -3.04, we must say that ANTX is in the distress zone and has some risk of bankruptcy.
  • ANTX has a Altman-Z score of -3.04. This is comparable to the rest of the industry: ANTX outperforms 41.36% of its industry peers.
  • ANTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.04
ROIC/WACCN/A
WACCN/A
ANTX Yearly LT Debt VS Equity VS FCFANTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • ANTX has a Current Ratio of 9.33. This indicates that ANTX is financially healthy and has no problem in meeting its short term obligations.
  • ANTX has a Current ratio of 9.33. This is in the better half of the industry: ANTX outperforms 78.01% of its industry peers.
  • A Quick Ratio of 9.33 indicates that ANTX has no problem at all paying its short term obligations.
  • The Quick ratio of ANTX (9.33) is better than 78.01% of its industry peers.
Industry RankSector Rank
Current Ratio 9.33
Quick Ratio 9.33
ANTX Yearly Current Assets VS Current LiabilitesANTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ANTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.86%, which is quite impressive.
EPS 1Y (TTM)42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ANTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.91% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.34%
EPS Next 2Y19.75%
EPS Next 3Y14.53%
EPS Next 5Y2.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANTX Yearly EPS VS EstimatesANTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ANTX. In the last year negative earnings were reported.
  • Also next year ANTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANTX Price Earnings VS Forward Price EarningsANTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANTX Per share dataANTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ANTX's earnings are expected to grow with 14.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.75%
EPS Next 3Y14.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ANTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AN2 THERAPEUTICS INC

NASDAQ:ANTX (2/19/2026, 8:00:01 PM)

After market: 1.0954 +0.01 (+0.5%)

1.09

+0.06 (+5.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-16
Inst Owners39.36%
Inst Owner Change0.54%
Ins Owners10.48%
Ins Owner Change-0.97%
Market Cap29.87M
Revenue(TTM)N/A
Net Income(TTM)-33.98M
Analysts43.33
Price Target1.02 (-6.42%)
Short Float %0.26%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.01%
Min EPS beat(2)-38.15%
Max EPS beat(2)38.17%
EPS beat(4)2
Avg EPS beat(4)-7.05%
Min EPS beat(4)-38.15%
Max EPS beat(4)38.17%
EPS beat(8)6
Avg EPS beat(8)5%
EPS beat(12)8
Avg EPS beat(12)3.24%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB 0.49
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS2.2
TBVpS2.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.55%
ROE -56.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.03%
ROA(5y)-106.84%
ROE(3y)-53.15%
ROE(5y)-145.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.33
Quick Ratio 9.33
Altman-Z -3.04
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
EPS Next Y30.34%
EPS Next 2Y19.75%
EPS Next 3Y14.53%
EPS Next 5Y2.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.52%
OCF growth 3YN/A
OCF growth 5YN/A

AN2 THERAPEUTICS INC / ANTX FAQ

What is the fundamental rating for ANTX stock?

ChartMill assigns a fundamental rating of 2 / 10 to ANTX.


What is the valuation status for ANTX stock?

ChartMill assigns a valuation rating of 0 / 10 to AN2 THERAPEUTICS INC (ANTX). This can be considered as Overvalued.


How profitable is AN2 THERAPEUTICS INC (ANTX) stock?

AN2 THERAPEUTICS INC (ANTX) has a profitability rating of 0 / 10.


Can you provide the financial health for ANTX stock?

The financial health rating of AN2 THERAPEUTICS INC (ANTX) is 7 / 10.